PTGS2
Prostaglandin G/H synthase 2
As of the edition of 20 October 2026, PTGS2 (prostaglandin G/H synthase 2, UniProt P35354) has 75 drugs tested at it and 111 companies on the list, 6 on route A and 28 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P35354
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 7
- Disease areas
- Cancer; Heart and blood vessels; Nervous system; Bones, joints and muscles; Digestive system; Urinary and reproductive; Skin and connective tissue; Immune system
- Registered trials of its drugs
- 3,638
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 52 |
| Went quiet | 8 |
| Stopped | 2 |
| Withdrawn from market | 11 |
| Status not established | 2 |
| Total | 75 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Acetaminophen | Marketed | Phase 4 | none listed |
| Aspirin | Marketed | Phase 4 | none listed |
| Ibuprofen | Marketed | Phase 4 | none listed |
| Celecoxib | Marketed | Phase 4 | none listed |
| Ketorolac | Marketed | Phase 4 | none listed |
| Diclofenac | Marketed | Phase 4 | none listed |
| Naproxen | Marketed | Phase 4 | none listed |
| Indomethacin | Marketed | Phase 4 | none listed |
| Mesalamine | Marketed | Phase 4 | Ends 2027 |
| Meloxicam | Marketed | Phase 4 | none listed |
| Etoricoxib | Marketed | Phase 4 | none listed |
| Ketoprofen | Marketed | Phase 4 | none listed |
12 of 75 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Route B | 28 |
| Engaged | 40 |
| Undetermined | 37 |
| Total on the list | 111 |
The other 108 companies at PTGS2
In the product111 companies in all; 108 are not named here, and no score is.
See the 111 companies at PTGS2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.